The Hyderabad based Covaxin maker Bharat Biotech is set to expand its manufacturing capacity to meet the growing need for vaccine supplies in the country.
The company has also sought financial help from the central government for increasing production to meet the growing demand across the country.
India’s ‘first’ indigenous Covid-19 vaccine, Covaxin, is co-developed by the Indian Council of Medical Research (ICMR) along with Hyderabad-based Bharat Biotech Ltd.
The company is now set to double the production at its existing plant in Hyderabad. It will also raise the vaccine production by five times at its facility at Malur Kolar in Bengaluru. It also has the option to use its Ankleshwar facility in Gujarat.
The plan is being overseen by a six-member inter-ministerial panel appointed by the Narendra Modi government to augment vaccine manufacturing in India as Covid cases see the second wave in the country.